<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340350</url>
  </required_header>
  <id_info>
    <org_study_id>RAM-01068</org_study_id>
    <nct_id>NCT03340350</nct_id>
  </id_info>
  <brief_title>Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans</brief_title>
  <official_title>Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sriram Ramaswamy</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Nebraska Western Iowa Health Care System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the safety and efficacy of adjunctive minocycline treatment in
      veterans with PTSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 12-week, open-label pilot study in which adjunctive minocycline will be
      administered to approximately 15 veterans diagnosed with PTSD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD Symptom Severity</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>PTSD symptom severity was assessed using total scores on the Past Month version of the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5). Total scores on the CAPS-5 range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in C-reactive Protein (CRP) Level</measure>
    <time_frame>Screening and Week 12</time_frame>
    <description>Measure of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Interleukin 6 (IL-6) Level</measure>
    <time_frame>Screening and Week 12</time_frame>
    <description>Measure of inflammation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tumor Necrosis Factor Alpha (TNF-Î±) Level</measure>
    <time_frame>Screening and Week 12</time_frame>
    <description>Measure of inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression Symptom Severity</measure>
    <time_frame>Screening and Week 12</time_frame>
    <description>Depression symptom severity was assessed using total scores on the Beck Depression Inventory-II (BDI-II). Total scores on the BDI-II range from 0 to 63, with higher scores indicating greater severity of depression symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status (Severity)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Clinical Global Impressions Severity scale (CGI-S) was used to assess severity of illness. Scores on the CGI-S range from 0 to 7, with higher scores reflecting greater severity of illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status (Improvement)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Clinical Global Impressions Improvement scale (CGI-I) was used to assess global improvement in clinical status. Scores on the CGI-I range from 0 to 7, with lower scores reflecting greater improvement in clinical status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive Functioning (Set Shifting)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Trail Making Test (TMT) is a scale used to measure a type of executive functioning (i.e., higher-order cognitive function) called set shifting. The TMT is scored as time (in seconds) to complete Parts A and B of this task. A difference score was calculated (time to complete Part B minus time to complete Part A) to subtract the motor component of this task and provide a better estimate of executive functioning. Lower difference scores on the TMT indicate better set shifting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive Functioning (Verbal Fluency)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The Controlled Oral Word Association (COWA) is a scale used to measure a type of executive functioning (i.e., higher-order cognitive function) called verbal fluency. The COWA is scored as the total number of valid words produced in one minute for each of three letters, with 1 point scored for each valid word (score range: 0-no upper limit). Higher scores on the COWA indicate greater verbal fluency.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline capsule</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Minocycline hydrochloride capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Veterans between the ages of 19 and 65 who meet Diagnostic and Statistical Manual of
             Mental Disorders, Fifth Edition (DSM-5) criteria for chronic PTSD.

          2. Patients who have been taking an adequate dose of selective serotonin reuptake
             inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) medication,
             bupropion, or mirtazapine for a minimum of 8 weeks at the time of study entry.

          3. PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth
             Edition (PCL-5) score of &gt; 33 at the Screening Visit. Eligible persons will be allowed
             to have other symptoms that are commonly comorbid with PTSD (e.g., anxiety, somatic
             symptoms). This strategy will provide a feasible and generalizable sample of those
             with chronic PTSD.

        Exclusion Criteria:

          1. Patients with a concurrent DSM-5 diagnosis in any of the following categories:

             1.1. Major Neurocognitive Disorder (NCD) 1.2. Lifetime Schizophrenia and other
             Psychotic Disorders 1.3. Lifetime Bipolar Disorder 1.4. Alcohol Dependence or Abuse in
             3 months prior to the Screening Visit 1.5. Any other Substance Dependence or Abuse
             (excluding nicotine) in 12 months prior to the Screening Visit 1.6. Any other
             concurrent Axis I Disorder (including Major Depressive Disorder) must be secondary to
             the primary diagnosis of PTSD.

          2. Chronic pain levels requiring use of any opiate medications with the exception of
             Tramadol. Patients are allowed the use of Tramadol at 25-50 mg per day dosing.

          3. Any condition or disorder that may cause neuropsychiatric sequelae (e.g., Parkinson's
             disease, stroke, seizures, or TBI).

          4. Past chronic PTSD, meaning PTSD that preceded the incident traumatic event responsible
             for the current PTSD. Other traumatic life events will not be exclusionary unless they
             resulted in previous PTSD.

          5. Patients with a history of intolerance or hypersensitivity to minocycline or other
             tetracycline antibiotics, or prior tetracycline use 2 months prior to the Screening
             Visit.

          6. Concomitant treatment with penicillin or other antibiotics, or treatment with
             antibiotics for greater than 7 days in the past month.

          7. Use of aspirin, non-steroidal anti-inflammatory agents (NSAIDs) or cyclooxygenase-2
             (COX-2) inhibitors for &lt; 6 months prior to study entry or dose changes after study
             entry. Limited as-needed use is permitted prior to study entry but not during the
             study.

          8. Use of statins will not be permitted during the study as they have been shown to
             reduce levels of pro-inflammatory cytokines.

          9. Use of concomitant anti-coagulant drugs (except low-dose aspirin) as minocycline has
             been shown to depress plasma prothrombin activity.

         10. Any degree of hepatic or renal failure that in the Investigator's judgement would pose
             a safety risk for treatment with minocycline.

         11. Conditions which may be negatively affected by minocycline treatment, such as active
             inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease).

         12. A history of C. difficile colitis.

         13. Patients who based on history or mental status examination have a significant risk of
             committing suicide, or who are homicidal or violent and who are in the Investigator's
             opinion in significant imminent risk of hurting others.

         14. Patients who have a medical condition that, in the Investigator's opinion, would
             expose them to an increased risk of a significant adverse event or interfere with
             assessments of safety and efficacy during the course of the trial.

         15. Women who are pregnant or plan to become pregnant during the study. All women of
             childbearing potential must have a negative urine pregnancy test at the Screening
             Visit and throughout the study. Sexually active women participating in the study must
             use a medically acceptable form of contraception.

         16. Patients with a current known infection or who are acutely ill.

         17. Patients with an autoimmune disease (i.e., Lupus, Rheumatoid Arthritis).

         18. Immunocompromised patients (i.e., HIV).

         19. Patients with thyroid disorders unless euthyroid at screening.

         20. Patients with cancer not in remission.

         21. Patients with cardiovascular disease, such as myocardial infarction and arrhythmias.

         22. Patients with diabetes.

         23. History of significant esophagitis.

         24. Patients who plan to initiate or terminate any psychotropic medication during the
             study. Patients taking any psychotropic medication should be on a stable dose for at
             least 6 weeks prior to the Screening Visit (except for the SSRI, SNRI or mirtazapine
             used to treat their PTSD) AND agree not to discontinue or otherwise alter treatment
             during the study.

         25. Patients who plan to initiate or terminate any form of psychotherapy or behavior
             therapy during the study with the exception of PTSD Orientation Group. Subjects may be
             in supportive psychotherapy if it was initiated at least three months prior to the
             Screening Visit AND subject agrees not to discontinue or otherwise alter therapy
             during the study. Subjects receiving evidence-based psychotherapies such as Prolonged
             Exposure or Cognitive Processing Therapy will be excluded.

         26. Patients who are unable to speak, read, and understand English or are judged by the
             Investigator to be unable or unlikely to follow the study protocol and complete all
             scheduled visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Ramaswamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Nebraska Western Iowa Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Nebraska-Western Iowa Health Care System</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <results_first_submitted>May 20, 2020</results_first_submitted>
  <results_first_submitted_qc>May 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2020</results_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>VA Nebraska Western Iowa Health Care System</investigator_affiliation>
    <investigator_full_name>Sriram Ramaswamy</investigator_full_name>
    <investigator_title>Staff Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Minocycline</keyword>
  <keyword>PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03340350/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Minocycline</title>
          <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Minocycline</title>
          <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PTSD Symptom Severity</title>
        <description>PTSD symptom severity was assessed using total scores on the Past Month version of the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5). Total scores on the CAPS-5 range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Participants received minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>PTSD Symptom Severity</title>
          <description>PTSD symptom severity was assessed using total scores on the Past Month version of the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5). Total scores on the CAPS-5 range from 0 to 80, with higher scores indicating greater severity of PTSD symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in C-reactive Protein (CRP) Level</title>
        <description>Measure of inflammation</description>
        <time_frame>Screening and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (CRP) Level</title>
          <description>Measure of inflammation</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Interleukin 6 (IL-6) Level</title>
        <description>Measure of inflammation</description>
        <time_frame>Screening and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Interleukin 6 (IL-6) Level</title>
          <description>Measure of inflammation</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Tumor Necrosis Factor Alpha (TNF-Î±) Level</title>
        <description>Measure of inflammation</description>
        <time_frame>Screening and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tumor Necrosis Factor Alpha (TNF-Î±) Level</title>
          <description>Measure of inflammation</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Symptom Severity</title>
        <description>Depression symptom severity was assessed using total scores on the Beck Depression Inventory-II (BDI-II). Total scores on the BDI-II range from 0 to 63, with higher scores indicating greater severity of depression symptoms.</description>
        <time_frame>Screening and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Symptom Severity</title>
          <description>Depression symptom severity was assessed using total scores on the Beck Depression Inventory-II (BDI-II). Total scores on the BDI-II range from 0 to 63, with higher scores indicating greater severity of depression symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.75" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status (Severity)</title>
        <description>The Clinical Global Impressions Severity scale (CGI-S) was used to assess severity of illness. Scores on the CGI-S range from 0 to 7, with higher scores reflecting greater severity of illness.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status (Severity)</title>
          <description>The Clinical Global Impressions Severity scale (CGI-S) was used to assess severity of illness. Scores on the CGI-S range from 0 to 7, with higher scores reflecting greater severity of illness.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status (Improvement)</title>
        <description>The Clinical Global Impressions Improvement scale (CGI-I) was used to assess global improvement in clinical status. Scores on the CGI-I range from 0 to 7, with lower scores reflecting greater improvement in clinical status.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status (Improvement)</title>
          <description>The Clinical Global Impressions Improvement scale (CGI-I) was used to assess global improvement in clinical status. Scores on the CGI-I range from 0 to 7, with lower scores reflecting greater improvement in clinical status.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Executive Functioning (Set Shifting)</title>
        <description>The Trail Making Test (TMT) is a scale used to measure a type of executive functioning (i.e., higher-order cognitive function) called set shifting. The TMT is scored as time (in seconds) to complete Parts A and B of this task. A difference score was calculated (time to complete Part B minus time to complete Part A) to subtract the motor component of this task and provide a better estimate of executive functioning. Lower difference scores on the TMT indicate better set shifting.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Executive Functioning (Set Shifting)</title>
          <description>The Trail Making Test (TMT) is a scale used to measure a type of executive functioning (i.e., higher-order cognitive function) called set shifting. The TMT is scored as time (in seconds) to complete Parts A and B of this task. A difference score was calculated (time to complete Part B minus time to complete Part A) to subtract the motor component of this task and provide a better estimate of executive functioning. Lower difference scores on the TMT indicate better set shifting.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.75" spread="11.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.00" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Executive Functioning (Verbal Fluency)</title>
        <description>The Controlled Oral Word Association (COWA) is a scale used to measure a type of executive functioning (i.e., higher-order cognitive function) called verbal fluency. The COWA is scored as the total number of valid words produced in one minute for each of three letters, with 1 point scored for each valid word (score range: 0-no upper limit). Higher scores on the COWA indicate greater verbal fluency.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Minocycline</title>
            <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Executive Functioning (Verbal Fluency)</title>
          <description>The Controlled Oral Word Association (COWA) is a scale used to measure a type of executive functioning (i.e., higher-order cognitive function) called verbal fluency. The COWA is scored as the total number of valid words produced in one minute for each of three letters, with 1 point scored for each valid word (score range: 0-no upper limit). Higher scores on the COWA indicate greater verbal fluency.</description>
          <units>number of words</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" spread="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.25" spread="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Minocycline</title>
          <description>Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Minocycline: Minocycline capsule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/hives</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sriram Ramaswamy, MD</name_or_title>
      <organization>VA Nebraska-Western Iowa Health Care System</organization>
      <phone>402-995-4712</phone>
      <email>Sriram.Ramaswamy@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

